Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Allison Berger"'
Autor:
Thea Kalebic, Neeraj Gupta, Lillian L. Siu, John S. Kauh, David Smith, Feng Gao, Ai Min Hui, Jeffrey R. Infante, Gordana Vlahovic, Allison Berger, Jianchang Lin, John A. Thompson, Deborah Berg, Guohui Liu, Stephen Tirrell, Daniel C. Sullivan, Alessandra Di Bacco
Publikováno v:
Investigational New Drugs
SummaryPurpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, i
Autor:
Nur Bruss, Allison Berger, Cody Paiva, Stephen E. Spurgeon, Taylor Rowland, Scott R Best, Alexey V. Danilov
Publikováno v:
Blood. 132:1867-1867
Introduction: Despite the promise of B-cell receptor-associated kinase inhibitors (BCRi) in CLL, resistance to these agents is inevitable. Ubiquitin-proteasome systems are altered in cancer, leading to destabilization of tumor suppressors, overexpres
Autor:
Yiguo Hu, Samir B. Amin, Dharminder Chauhan, Yu-Tzu Tai, Ze Tian, Allison Berger, Paul G. Richardson, Kenneth C. Anderson, Jianjun Zhao
Publikováno v:
Blood. 120:3958-3967
miRs play a critical role in tumor pathogenesis as either oncogenes or tumor-suppressor genes. However, the role of miRs and their regulation in response to proteasome inhibitors in multiple myeloma (MM) is unclear. In the current study, miR profilin
Autor:
Bret Bannerman, Larry Dick, Mark Rolfe, Li Yu, Paul Hales, Jie Yu, Frank J. Bruzzese, Mark Manfredi, Edmund Lee, Michael Fitzgerald, Yueying Cao, Khristofer Garcia, Jane Liu, Joe Bolen, Erik Kupperman, Jonathan L. Blank, Paul E. Fleming, Yu Yang, Christopher Tsu, Allison Berger
Publikováno v:
Cancer Research. 70:1970-1980
The proteasome was validated as an oncology target following the clinical success of VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring mantle cell lymphoma. Consequently, severalgroups are pursuing the development
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Lunyin Yu Yu, Dirk Huebner, Yuhong Zhang, Jie Yu, Stephen Tirrell, Dan He McDougall, Helgi van de Velde, Allison Berger, Sakeena Syed, Christopher Tremblay, Nibedita Chattopadhyay
Publikováno v:
Blood. 128:1842-1842
The ubiquitin-proteasome system (UPS) represents the primary mechanism by which cells degrade proteins. Proteasome inhibition results in accumulation of proteasome substrates, leading to cell cycle disruption, endoplasmic reticulum (ER) stress, activ
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Autor:
Thomas J. Waldschmidt, Michael R. Acevedo, Van S. Tompkins, Ramakrishna Sompallae, Kaylia Duncan, Alicia K. Olivier, Siegfried Janz, Herbert C. Morse, Guido Tricot, Lorraine T. Tygrett, Susan A. Walsh, Allison Berger, Laura L. Boles Ponto, John Sunderland, Fenghuang Zhan, Timothy R. Rosean
Publikováno v:
Blood Cancer Journal
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the
Autor:
Min Yang, David Tamang, Simon S. Jones, Steven N. Quayle, Khristofer Garcia, Jeffrey Ciavarri, Jie Yu, Allison Berger, Bret Bannerman
Publikováno v:
Blood. 122:4437-4437
Introduction The combination of HDAC inhibitors and proteasome inhibitors has demonstrated preclinical benefit in several settings, including multiple myeloma and lymphoma, and is being explored in clinical trials testing various HDAC inhibitors in c
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som